FDA Approved: ELZONRIS — Original Application (Stemline Therapeutics, Inc.)

View source ↗

Summary

FDA approves ELZONRIS (tagraxofusp) from Stemline Therapeutics in the original application for blastic plasmacytoid dendritic cell neoplasm (BPDCN).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Blastic Plasmacytoid Dendritic Cell Neoplasm

Drugs mentioned

• Elzonris (tagraxofusp)

Snippet

ORIG AP for ELZONRIS (TAGRAXOFUSP)